Λογότυπο www.galinos.gr Beta
 

Ιατροφαρμακευτική πληροφόρηση για τον επαγγελματία υγείας

Φάρμακα Δραστικές ουσίες Συμπληρώματα διατροφής Έλεγχος συγχορήγησης Νόσοι ICD-10
Κλαύδιος Γαληνός
Είσοδος χρηστών
Όνομα χρήστη
Συνθηματικό
Εικονίδιο Είσοδος χρήστη
Εικονίδιο Δωρεάν εγγραφή
Εικονίδιο Ανανέωση συνθηματικού

Ακολουθήστε μας Λογότυπο Facebook Λογότυπο Twitter

Αναζήτηση σε 63811 καταχωρήσεις
Εικονίδιο αναζήτησης

Βιβλιογραφική αναφορά

Προτάσεις

SPC, Greece: Atenativ Pwd. Sol. (2007)

Σφάλμα Για την προβολή της πλήρους καταχώρησης χρειάζεται να έχετε συνδρομή σε ισχύ (αγορά συνδρομής).
Ολοκληρώνοντας τη διαδικασία δωρεάν εγγραφής θα αποκτήσετε, χωρίς καμία δέσμευση εκ μέρους σας, συνδρομή διάρκειας 30 ημερών.

Περιεχόμενα

Name of the medicinal product

Atenativ 50 IU/mL, powder and solvent for solution for infusion.

Qualitative and quantitative composition

Atenativ is presented as a powder and solvent for solution for infusion containing 500 IU, 1000 IU or ...

Pharmaceutical form

Powder and solvent for solution for infusion. Atenativ is supplied in freeze-dried form. The concentrate ...

Therapeutic indications

Patients with congenital deficiency. a) Prophylaxis of deep vein thrombosis and thromboembolism in clinical ...

Posology and method of administration

Treatment should be initiated under the supervision of a physician experienced in the treatment of patients ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Special warnings and precautions for use

Antithrombin should be administered restrictively in connection with acquired antithrombin deficiency ...

Interaction with other medicinal products and other forms of interaction

Heparin: antithrombin replacement during administration of heparin in therapeutic dosage increases the ...

Pregnancy and lactation

Experience as to the safety of human antithrombin products for use in human pregnancy is limited. Atenativ ...

Effects on ability to drive and use machines

No effects on ability to drive and use machines have been observed.

Undesirable effects

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion ...

Overdose

No symptoms of overdose with antithrombin have been reported.

Pharmacodynamic properties

Pharmacotherapeutic Group: Antithrombotic agents, heparin group ATC Code: B01AB02 Antithrombin, a 58 ...

Pharmacokinetic properties

Pharmacokinetic studies with Atenativ have shown a mean biological half life of about 3 days. The half ...

Preclinical safety data

Atenativ contains trace amounts of the chemicals tributyl phosphate and octoxynol, which are used during ...

List of excipients

Sodium chloride Human albumin Acetyltryptophan Sodium caprylate Solvent/Diluent: water for injection. ...

Incompatibilities

Atenativ should not be mixed with other medicinal products.

Shelf life

Shelf life: 36 months (infusion vial). The reconstituted solution should be used within 12 hours.

Special precautions for storage

To be stored at 2°C to 8°C. Within its shelf-life the product may be stored at 25°C for up to one month, ...

Nature and contents of container

Injection vial of type II glass (Ph.Eur.), 50 or 100 mL with a bromobutyl rubber stopper sealed with ...

Special precautions for disposal and other handling

The freeze-dried powder is reconstituted in sterile water for injection. After reconstitution Atenativ ...

Date of revision of the text

02/2007
Απαγορεύεται η αναπαραγωγή και αναδιανομή. Το έργο επεξεργασίας των παραπάνω πληροφοριών αποτελεί πνευματική ιδιοκτησία της Ergobyte Πληροφορική Α.Ε. και προστατεύεται από τη νομοθεσία περί πνευματικών δικαιωμάτων.